RSS

combination therapy

Healthcare solutions provider, Novartis, has announced that the European Commission has approved its combination therapy, Tafinlar + Mekinist, for adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

A combination of drugs has offered promising results in an early clinical trial, where it has shrunk tumours in ovarian and lung cancer patients and prevented tumour growth for nearly six months. more

News

Biotechnology company, Genmab, has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnos more

News

Two drugs, to be administered together for the treatment of ATC that cannot be surgically removed or has spread and has a type of abnormal gene, BRAF V600E, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the FDA more

News

A strategic partnership has been formed between scientists from Emulate and Roche (F Hoffman La-Roche) for the application of organ-chips in the testing of the efficacy and safety of new antibody therapeutics and combination therapies. more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Italian pharmaceutical company, NTC, has entered into a commercial partnership with Santen Pharmaceutical — a pharma company focused on ophthalmology. more

News

British biopharmaceuticals company, Helperby Therapeutics, has developed a sustainable solution to combat antimicrobial resistance — Antibiotic Resistance Breakers (ARBs) — which may reach the market as early as 2020. more

Technology

A study, from an international team of researchers, may offer hope to patients with prostate cancer as it shows that a combination therapy could potentially reduce the recurrence rate of the disease. more

News

Eli Lilly and Company has announced that the National Institute for Health and Care Excellence (NICE) has recommended olaratumab (Lartruvo▼) in combination with doxorubicin as a treatment for advanced soft tissue sarcoma in adults more

News

Sanofi will extend its alliance with Medicines for Malaria Venture to jointly develop a fixed-dose combination therapy for malaria, the deadliest parasitic disease in the world. more

News